Oxford Nanopore Technologies (LON:ONT) saw shares rise more than 6% after the company announced full‑year revenue would exceed guidance. The gene‑sequencing firm projected 2025 revenue of £223‑£224 million, a 22% jump on a reported basis, beating consensus of £220 million. Growth spread across Europe, Middle East, Africa, India, Asia Pacific and the Americas, with clinical sales up 30% and bio‑pharma revenue rising similarly.

The PromethION platform led the charge, posting 40% year‑over‑year growth, while MinION returned to expansion thanks to quality‑control demand. Analysts noted that the company’s EBITDA breakeven target of 2027 and cash‑flow breakeven of 2028 remain unchanged. Year‑end cash and liquid investments fell to £302 million from £404 million, yet still above the £281 million consensus, reflecting working‑capital gains and a shift toward capital‑equipment sales.

The result signals that Oxford Nanopore’s commercial momentum is steady, positioning it to capitalize on the growing demand for rapid, on‑site sequencing in clinical and industrial settings ahead today.